Press Resease

Platelet Rich Plasma Market by Type (Pure Platelet-Rich Plasma, Leukocyte-Rich Platelet-Rich Plasma, Pure Platelet-Rich Fibrin, and Leukocyte-Rich Platelet-Rich Fibrin), by Origin (Autologous PRP, Allogeneic PRP, and Homologous PRP), by Application (Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury, and Others), and by End-User (Hospitals & Clinics and Research Institutions): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 – 2024

Published Date: 30-Oct-2018 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3484 Status : Published

Global platelet rich plasma market expected to generate revenue of around USD 438 million by the end of 2024, growing at a CAGR of around 12.90% between 2018 and 2024. Plasma rich platelets contain a high concentration of platelets, which are suspended in plasma after centrifugation. PRP promotes the healing of soft tissues after the growth factors are released.

Description

The report covers the forecast and analysis for the platelet rich plasma market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes the drivers and restraints for the platelet rich plasma market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the platelet rich plasma market on a global level.

In order to give the users of this report a comprehensive view of the platelet rich plasma market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Platelet Rich Plasma Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market, including acquisitions and mergers, new service type launch, agreements, partnerships, collaborations, and joint ventures, research and development, service type, and regional expansion of major participants involved in the market.

The study provides a decisive view of the platelet rich plasma market by segmenting it based on type, origin, application, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further categorization into major countries including the U.S., UK, Germany, France, China, Japan, India, Brazil, etc. This segmentation includes the demand for platelet rich plasma market based on all the segments in all the regions and countries.

The key players in the global platelet rich plasma market are Cambryn Biologics LLC, Regen Lab SA, Nuo Therapeutics, Inc., Cesca Therapeutics, Inc., Grifols International S.A., Octapharma, EmCyte Corporation, AdiStem Ltd., ISTO Biologics, and BioLife Plasma Services.

This report segments the global platelet rich plasma market as follows:

Global Platelet Rich Plasma Market: Type Segment Analysis

  • Pure Platelet-rich Plasma
  • Leukocyte-rich Platelet-rich Plasma
  • Pure Platelet-rich Fibrin
  • Leukocyte-rich Platelet-rich Fibrin

Global Platelet Rich Plasma Market: Origin Segment Analysis

  • Allogeneic PRP
  • Autologous PRP
  • Homologous PRP

Global Platelet Rich Plasma Market: Application Segment Analysis

  • Orthopedics
  • Dermatology
  • Dental
  • Cardiac Muscle Injury
  • Nerve Injury
  • Others

Global Platelet Rich Plasma Market: End-user Segment Analysis

  • Hospitals & Clinics
  • Research Institutions

Global Platelet Rich Plasma Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global platelet rich plasma market, 2015 - 2024 (USD Million)
    • 2.2. Global platelet rich plasma market: Snapshot
  •  
  • Chapter 3. Platelet Rich Plasma Market - Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global platelet rich plasma market drivers: Impact analysis
      • 3.2.2. Growing use of PRP in various therapeutic areas
      • 3.2.3. Rising incidences of sport injuries
      • 3.2.4. Prevalence of Arthritis
      • 3.2.5. Less risk
    • 3.3. Market Restraints
      • 3.3.1. Global platelet rich plasma market restraints: Impact analysis
      • 3.3.2. Lack of reimbursement policies
      • 3.3.3. Varying Prices of the therapy
    • 3.4. Opportunities
      • 3.4.1. Rising Orthopedic Disorders
      • 3.4.2. Awareness in emerging economies
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. The threat from new entrants
      • 3.5.4. The threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by type segment
      • 3.6.2. Market attractiveness analysis, by origin segment
      • 3.6.3. Market attractiveness analysis, by application segment
      • 3.6.4. Market attractiveness analysis, by end-user segment
      • 3.6.5. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Platelet Rich Plasma Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global platelet rich plasma market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New material launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Platelet Rich Plasma Market -Type Segment Analysis
    • 5.1. Global platelet rich plasma market: Type overview
      • 5.1.1. Global platelet rich plasma market revenue share, by type, 2017 and 2024
    • 5.2. Pure Platelet-rich Plasma
      • 5.2.1. Global platelet rich plasma market for pure platelet-rich plasma, 2015 - 2024 (USD Million)
    • 5.3. Leukocyte-rich Platelet-rich Plasma
      • 5.3.1. Global platelet rich plasma market for leukocyte-rich platelet-rich plasma, 2015 - 2024 (USD Million)
    • 5.4. Pure Platelet-rich Fibrin
      • 5.4.1. Global platelet rich plasma market for bare metal stents, 2015 - 2024 (USD Million)
    • 5.5. Leukocyte-rich Platelet-rich Fibrin
      • 5.5.1. Global platelet rich plasma market for leukocyte-rich platelet-rich fibrin, 2015 - 2024 (USD Million)
  •  
  • Chapter 6. Global Platelet Rich Plasma Market - Origin Segment Analysis
    • 6.1. Global platelet rich plasma market: Origin overview
      • 6.1.1. Global platelet rich plasma market revenue share, by origin, 2017 and 2024
    • 6.2. Allogeneic PRP
      • 6.2.1. Global platelet rich plasma market for allogeneic PRP, 2015 - 2024 (USD Million)
    • 6.3. Autologous PRP
      • 6.3.1. Global platelet rich plasma market for autologous PRP, 2015 - 2024 (USD Million)
    • 6.4. Homologous PRP
      • 6.4.1. Global platelet rich plasma market for homologous PRP, 2015 - 2024 (USD Million)
  •  
  • Chapter 7. Global Platelet Rich Plasma Market - Application Segment Analysis
    • 7.1. Global platelet rich plasma market: Application overview
      • 7.1.1. Global platelet rich plasma market revenue share, by origin, 2017 and 2024
    • 7.2. Orthopedics
      • 7.2.1. Global platelet rich plasma market for orthopedics, 2015 - 2024 (USD Million)
    • 7.3. Dermatology
      • 7.3.1. Global platelet rich plasma market for dermatology, 2015 - 2024 (USD Million)
    • 7.4. Dental
      • 7.4.1. Global platelet rich plasma market for dental, 2015 - 2024 (USD Million)
    • 7.5. Cardiac Muscle Injury
      • 7.5.1. Global platelet rich plasma market for cardiac muscle injury, 2015 - 2024 (USD Million)
    • 7.6. Nerve Injury
      • 7.6.1. Global platelet rich plasma market for nerve injury, 2015 - 2024 (USD Million)
    • 7.7. Others
      • 7.7.1. Global platelet rich plasma market for others, 2015 - 2024 (USD Million)
  •  
  • Chapter 8. Global Platelet Rich Plasma Market -End-user Segment Analysis
    • 8.1. Global platelet rich plasma market: end-user overview
      • 8.1.1. Global platelet rich plasma market revenue share, by end-user, 2017 and 2024
    • 8.2. Hospitals & Clinics
      • 8.2.1. Global platelet rich plasma market for in-house, 2015 - 2024 (USD Million)
    • 8.3. Research Institutions
      • 8.3.1. Global platelet rich plasma market for research institutions, 2015 - 2024 (USD Million)
  •  
  • Chapter 9. Global Platelet Rich Plasma Market - Regional Segment Analysis
    • 9.1. Global platelet rich plasma market: Regional overview
      • 9.1.1. Global platelet rich plasma market revenue share, by region, 2017 and 2024
    • 9.2. North America
      • 9.2.1. North America platelet rich plasma market, 2015 - 2024 (USD Million)
      • 9.2.2. North America platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
      • 9.2.3. North America platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
      • 9.2.4. North America platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
      • 9.2.5. North America platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.2.6. The U.S.
        • 9.2.6.1. The U.S. platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.2.6.2. The U.S. platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.2.6.3. The U.S. platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.2.6.4. The U.S. platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.2.7. Canada
        • 9.2.7.1. Canada platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.2.7.2. Canada platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.2.7.3. Canada platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.2.7.4. Canada platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe platelet rich plasma market, 2015 - 2024 (USD Million)
      • 9.3.2. Europe platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
      • 9.3.3. Europe platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
      • 9.3.4. Europe platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
      • 9.3.5. Europe platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.3.6. UK
        • 9.3.6.1. UK platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.3.6.2. UK platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.3.6.3. UK platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.3.6.4. UK platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.3.7. Germany
        • 9.3.7.1. Germany platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.3.7.2. Germany platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.3.7.3. Germany platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.3.7.4. Germany platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.3.8. France
        • 9.3.8.1. France platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.3.8.2. France platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.3.8.3. France platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.3.8.4. France platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.3.9. Rest of Europe
        • 9.3.9.1. Rest of Europe platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.3.9.2. Rest of Europe platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.3.9.3. Rest of Europe platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.3.9.4. Rest of Europe platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific platelet rich plasma market, 2015 - 2024 (USD Million)
      • 9.4.2. Asia Pacific platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
      • 9.4.3. Asia Pacific platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
      • 9.4.4. Asia Pacific platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
      • 9.4.5. Asia Pacific platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.4.6. China
        • 9.4.6.1. China platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.4.6.2. China platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.4.6.3. China platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.4.6.4. China platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.4.7. Japan
        • 9.4.7.1. Japan platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.4.7.2. Japan platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.4.7.3. Japan platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.4.7.4. Japan platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.4.8. India
        • 9.4.8.1. India platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.4.8.2. India platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.4.8.3. India platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.4.8.4. India platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.4.9.2. Rest of Asia Pacific platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.4.9.3. Rest of Asia Pacific platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.4.9.4. Rest of Asia Pacific platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America platelet rich plasma market, 2015 - 2024 (USD Million)
      • 9.5.2. Latin America platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
      • 9.5.3. Latin America platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
      • 9.5.4. Latin America platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
      • 9.5.5. Latin America platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.5.6.2. Brazil platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.5.6.3. Brazil platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.5.6.4. Brazil platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
      • 9.5.7. Rest of Latin America
        • 9.5.7.1. Rest of Latin America platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
        • 9.5.7.2. Rest of Latin America platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
        • 9.5.7.3. Rest of Latin America platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
        • 9.5.7.4. Rest of Latin America platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
    • 9.6. The Middle East and Africa
      • 9.6.1. The Middle East and Africa platelet rich plasma market, 2015 - 2024 (USD Million)
      • 9.6.2. The Middle East and Africa platelet rich plasma market revenue, by type, 2015 - 2024 (USD Million)
      • 9.6.3. The Middle East and Africa platelet rich plasma market revenue, by origin, 2015 - 2024 (USD Million)
      • 9.6.4. The Middle East and Africa platelet rich plasma market revenue, by application, 2015 - 2024 (USD Million)
      • 9.6.5. The Middle East and Africa platelet rich plasma market revenue, by end-user, 2015 - 2024 (USD Million)
  •  
  • Chapter 10. Company Profile
    • 10.1. Cambryn Biologics LLC
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product Portfolio
      • 10.1.4. Business Strategy
      • 10.1.5. Recent Developments
    • 10.2. Regen Lab SA
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product Portfolio
      • 10.2.4. Business Strategy
      • 10.2.5. Recent Developments
    • 10.3. Nuo Therapeutics, Inc.
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product Portfolio
      • 10.3.4. Business Strategy
      • 10.3.5. Recent Developments
    • 10.4. Cesca Therapeutics, Inc.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product Portfolio
      • 10.4.4. Business Strategy
      • 10.4.5. Recent Developments
    • 10.5. Grifols International S.A.
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product Portfolio
      • 10.5.4. Business Strategy
      • 10.5.5. Recent Developments
    • 10.6. Octapharma
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product Portfolio
      • 10.6.4. Business Strategy
      • 10.6.5. Recent Developments
    • 10.7. EmCyte Corporation
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Product Portfolio
      • 10.7.4. Business Strategy
      • 10.7.5. Recent Developments
    • 10.8. AdiStem Ltd.
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product Portfolio
      • 10.8.4. Business Strategy
      • 10.8.5. Recent Developments
    • 10.9. ISTO Biologics
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Product Portfolio
      • 10.9.4. Business Strategy
      • 10.9.5. Recent Developments
    • 10.10. BioLife Plasma Services
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product Portfolio
      • 10.10.4. Business Strategy
      • 10.10.5. Recent Developments 

Methodology

Free Analysis

Platelet rich plasma (PRP) is a portion of plasma derived from the patient’s blood. This portion of blood has a high concentration of platelets, which promotes the healing of ligaments, muscles, joints, and tendons. PRP generally contains different growth factors and some cytokines that are responsible for initiating the healing of injuries.

According to the statistics by ISAPS (International Society of Plastic and Aesthetic Surgeons), in 2013, about 11 million cosmetic surgeries (non-invasive) were carried out across the world. According to the statistics, in 2015, about 617 million of the global population was aged above 65 years. Aging weakens the bones, which increases the chances of orthopedic impairments. The rise in the prevalence of orthopedic impairments and an increase in the number of cosmetic surgeries are expected to fuel the development of the global platelet rich plasma market. Additionally, the rise in the awareness about PRP therapy is anticipated to further contribute to this market’s growth globally. The rising occurrences of arthritis, technological advancement in PRP products and therapy, and support by government for the use of PRP therapies are some other factors driving the expansion of the global market for platelet rich plasma.

Global Platelet Rich Plasma Market

Platelet rich plasma market is segmented on the basis of type, origin, application, and end-user. Based on the type, this market is divided into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich platelet-rich fibrin. The pure PRP segment is anticipated to dominate the market in the forecast period. By origin, the market for platelet rich plasma is segmented into autologous PRP, homologous PRP, and allogeneic PRP. In 2017, the autologous PRP segment held the largest market share. By application, the platelet rich plasma market is divided cardiac muscle injury, orthopedics, dermatology, nerve injury, and others. The orthopedics segment is anticipated to lead the market for platelet rich plasma in the upcoming years. Based on end-user, the market for platelet rich plasma is segmented into hospitals and clinics and research institutes. The hospitals and clinics segment is projected to dominate the platelet rich plasma market.

North America is anticipated to lead the market for platelet rich plasma in the upcoming years, due to the increase in the number of cosmetic surgeries, rise in the cases of rheumatology, growing awareness about PRP therapy, and rapid approval by FDA for various platelet rich plasma products. In the forecast timeframe, the Asia Pacific region is anticipated to show the highest growth due to the increase in the number of people suffering from osteoporosis. The increasing number of accidents, growing awareness about technologically advance PRP products, and rising occurrences of neurological disorders are some other factors fueling the growth of the market in the Asia Pacific region.

The main players involved in the global platelet rich plasma market are Cambryn Biologics LLC, Regen Lab SA, Nuo Therapeutics, Inc., Cesca Therapeutics, Inc., Grifols International S.A., Octapharma, EmCyte Corporation, AdiStem Ltd., ISTO Biologics, and BioLife Plasma Services. These companies focus on the development of various products for the treatment of different diseases. For instance, in 2017, Cesca Therapeutics Inc. announced an autologous PRP which is used for the treatment of chronic ulcers.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social